# US 2017/0360832 A1 · Hypochlorous acid formulations and methods for treating skin conditions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0360832 A1
- Document ID: US20170360832A1
- Status: Published application
- Kind: A1
- Application number: 15/535,555
- Filed: 2015-12-16
- Published: 2017-12-21
- Earliest claimed: 2014-12-16
- Assignees: Realm Therapeutics, Inc.
- Applicants: Realm Therapeutics, Inc.
- Inventors: Mark SAMPSON; Svetlana PANICHEVA; Cary SCHOCKEMOEHL
- Web page: https://patentgrep.com/patent/US20170360832A1

## CPC

- A61K 33/20: Elemental chlorine; Inorganic compounds releasing chlorine
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 2300/00: Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention in various aspects and embodiments provides methods and formulations for treating inflammatory conditions of the skin and/or conditions involving compromised skin barrier function. Such diseases include blistering diseases of the skin, hereditary defects in skin barrier function, hyperproliferative conditions involving the skin, conditions associated with aging or damaged skin, immunological disorders involving the skin, among others.

## Claims

### Claim 1

A method for treating a blistering skin disease, comprising: applying to the affected areas of the skin a hypochlorous acid formulation having an amount of hypochlorous acid effective to reduce or inhibit inflammatory and/or immune processes.

### Claim 2 (depends on 1)

The method of claim 1, wherein the formulation has AFC of at least about 300 ppm.

### Claim 3 (depends on 1)

The method of claim 1, wherein the formulation has AFC of at least about 500 ppm.

### Claim 4 (depends on 1)

The method of claim 1, wherein the formulation has AFC of at least about 700 ppm.

### Claim 5 (depends on 1)

The method of claim 1, wherein the formulation has AFC of at least about 1000 ppm.

### Claim 6 (depends on 1)

The method of claim 1, wherein the formulation has AFC in the range of about 500 to about 1500 ppm.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The method of any one of claims 1 to 6, wherein the formulation has a pH of from about 5 to about 7.

### Claim 8 (depends on 7)

The method of claim 7, wherein the formulation has a pH of from about 5.4 to about 6.4.

### Claim 9 (depends on 7)

The method of claim 7, wherein the formulation has a pH of from about 5.0 to about 6.4.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The method of any one of claims 1 to 9, wherein the blistering disease is Bullous pemphigoid.

### Claim 11 (depends on 10)

The method of claim 10, wherein the formulation is applied as an alternative or adjunct therapy to topical or oral corticosteroid.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The method of any one of claims 1 to 9, wherein the blistering disease is Epidermolysis Bullosa.

### Claim 13 (depends on 12)

The method of claim 12, wherein the formulation is applied as an alternative or adjunct therapy to topical or oral corticosteroid and/or topical or oral antibiotic.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The method of claims 1 to 9, wherein the blistering disease is associated with an autoimmune condition.

### Claim 15 (depends on 14)

The method of claim 14, wherein the blistering disease is dermatitis herpetiformis.

### Claim 16 (depends on 14)

The method of claim 14, wherein the formulation is applied as an alternative or adjunct therapy to topical or oral corticosteroid and/or immunosuppressant or immunomodulator.

### Claim 17 (depends on 14)

The method of claim 14, wherein the blistering disease is Systemic Lupus Erythematosus (SLE).

### Claim 18 (depends on 17)

The method of claim 17, wherein the formulation is applied as an alternative or adjunct therapy to topical or oral corticosteroid.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The method of any one of claims 1 to 18, wherein the hypochlorous acid formulation is applied to affected areas from 1 to about 10 times daily.

### Claim 20 (depends on 19)

The method of claim 19, wherein the hypochlorous acid formulation is applied to affected areas from 1 to about 5 times daily.

### Claim 21 (depends on 19)

The method of claim 19, wherein the hypochlorous acid formulation is applied to affected areas from 1 to 3 times daily.

### Claim 22 (depends on 19, 20, 21)

The method of any one of claims 19 to 21, wherein the hypochlorous acid formulation is applied periodically to control symptoms or flare-ups.

### Claim 23 (depends on 22)

The method of claim 22, wherein the hypochorous acid formulation is applied in a regimen that lasts for 1 to about 12 weeks.

### Claim 24 (depends on 22)

The method of claim 22, wherein the hypochlorous acid formulation is applied in a regimen that lasts for 1 to about 8 weeks.

### Claim 25 (depends on 22)

The method of claim 22, wherein the hypochlorous acid formulation is applied in a regimen that lasts for 1 to about 4 weeks.

### Claim 26

A method for treating a hereditary defect in skin barrier function, comprising: applying to the affected areas of the skin a hypochlorous acid formulation having an amount of hypochlorous acid effective to reduce or inhibit inflammatory and/or immune processes.

### Claim 27 (depends on 26)

The method of claim 26, wherein the formulation has AFC of at least about 300 ppm.

### Claim 28 (depends on 26)

The method of claim 26, wherein the formulation has AFC of at least about 500 ppm.

### Claim 29 (depends on 26)

The method of claim 26, wherein the formulation has AFC of at least about 700 ppm.

### Claim 30 (depends on 26)

The method of claim 26, wherein the formulation has AFC of at least about 1000 ppm.

### Claim 31 (depends on 26)

The method of claim 26, wherein the formulation has AFC in the range of about 500 to about 1500 ppm.

### Claim 32 (depends on 26, 27, 28, 29, 30, 31)

The method of any one of claims 26 to 31, wherein the formulation has a pH of from about 5 to about 7.

### Claim 33 (depends on 32)

The method of claim 32, wherein the formulation has a pH of from about 5.4 to about 6.4.

### Claim 34 (depends on 32)

The method of claim 32, wherein the formulation has a pH of from about 5.0 to about 6.4.

### Claim 35 (depends on 26, 27, 28, 29, 30, 31, 32, 33, 34)

The method of any one of claims 26 to 34, wherein the hereditary defect in skin barrier function is Netherton Syndrome.

### Claim 36 (depends on 26, 27, 28, 29, 30, 31, 32, 33, 34)

The method of any one of claims 26 to 34, wherein the hereditary defect in skin barrier function is Ichthyosis.

### Claim 37 (depends on 26, 27, 28, 29, 30, 31, 32, 33, 34)

The method of any one of claims 26 to 34, wherein the hereditary defect in skin barrier function is palmoplantar hyperkeratinosis.

### Claim 38 (depends on 26, 27, 28, 29, 30, 31, 32, 33, 34)

The method of any one of claims 26 to 34, wherein the hypochlorous acid formulation is applied to affected areas from 1 to about 10 times daily.

### Claim 39 (depends on 38)

The method of claim 38, wherein the hypochlorous acid formulation is applied to affected areas from 1 to about 5 times daily.

### Claim 40 (depends on 38)

The method of claim 38, wherein the hypochlorous acid formulation is applied to affected areas from 1 to about 3 times daily.

### Claim 41 (depends on 38, 39, 40)

The method of any one of claims 38 to 40, wherein the hypochlorous acid formulation is applied periodically to control symptoms or flare-ups.

### Claim 42 (depends on 41)

The method of claim 41, wherein the hypochlorous acid formulation is applied in a regimen that lasts for 1 to about 12 weeks.

### Claim 43 (depends on 41)

The method of claim 41, wherein the hypochlorous acid formulation is applied in a regimen that lasts for 1 to about 8 weeks.

### Claim 44 (depends on 41)

The method of claim 41, wherein the hypochlorous acid formulation is applied in a regimen that lasts for 1 to about 4 weeks.

### Claim 45

A method for treating a hyperproliferative condition involving the skin, comprising: applying to the affected areas of the skin a hypochlorous acid formulation having an amount of hypochlorous acid effective to reduce or inhibit inflammatory and/or immune processes.

### Claim 46 (depends on 45)

The method of claim 45, wherein the formulation has AFC of at least about 300 ppm.

### Claim 47 (depends on 45)

The method of claim 45, wherein the formulation has AFC of at least about 500 ppm.

### Claim 48 (depends on 45)

The method of claim 45, wherein the formulation has AFC of at least about 700 ppm.

### Claim 49 (depends on 45)

The method of claim 45, wherein the formulation has AFC of at least about 1000 ppm.

### Claim 50 (depends on 45)

The method of claim 45, wherein the formulation has AFC in the range of about 500 to about 1500 ppm.

### Claim 51 (depends on 45, 46, 47, 48, 49, 50)

The method of any one of claims 45 to 50, wherein the formulation has a pH of from about 5 to about 7.

### Claim 52 (depends on 51)

The method of claim 51, wherein the formulation has a pH of from about 5.4 to about 6.4.

### Claim 53 (depends on 51)

The method of claim 51, wherein the formulation has a pH of from about 5.0 to about 6.4.

### Claim 54 (depends on 45, 46, 47, 48, 49, 50, 51, 52, 53)

The method of any one of claims 45 to 53, wherein the condition is squamous cell carcinoma (SCC).

### Claim 55 (depends on 45, 46, 47, 48, 49, 50, 51, 52, 53)

The method of any one of claims 45 to 53, wherein the condition is basal cell carcinoma (BCC).

### Claim 56 (depends on 45, 46, 47, 48, 49, 50, 51, 52, 53)

The method of any one of claims 45 to 53, wherein the condition is cutaneous T-cell Lymphoma.

### Claim 57 (depends on 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56)

The method of any one of claims 45 to 56, wherein the hypochlorous acid formulation is applied to affected areas from 1 to about 10 times daily.

### Claim 58 (depends on 57)

The method of claim 57, wherein the hypochlorous acid formulation is applied to affected areas from 1 to about 5 times daily.

### Claim 59 (depends on 57)

The method of claim 57, wherein the hypochlorous acid formulation is applied to affected areas from 1 to about 3 times daily.

### Claim 60 (depends on 57, 58, 59)

The method of any one of claims 57 to 59, wherein the hypochorous acid formulation is applied in a regimen that lasts for 1 to about 12 weeks.

### Claim 61 (depends on 60)

The method of claim 60, wherein the hypochlorous acid formulation is applied in a regimen that lasts for 1 to about 8 weeks.

### Claim 62 (depends on 60)

The method of claim 60, wherein the hypochlorous acid formulation is applied in a regimen that lasts for 1 to about 4 weeks.

### Claim 63

A method for treating inflammation associated with aging or damaged skin, comprising: applying to the affected areas of the skin a hypochlorous acid formulation having an amount of hypochlorous acid effective to reduce or inhibit inflammatory and/or immune processes.

### Claim 64 (depends on 63)

The method of claim 63, wherein the formulation has AFC of at least about 300 ppm.

### Claim 65 (depends on 63)

The method of claim 63, wherein the formulation has AFC of at least about 500 ppm.

### Claim 66 (depends on 63)

The method of claim 63, wherein the formulation has AFC of at least about 700 ppm.

### Claim 67 (depends on 63)

The method of claim 63, wherein the formulation has AFC of at least about 1000 ppm.

### Claim 68 (depends on 63)

The method of claim 63, wherein the formulation has AFC in the range of about 500 to about 1500 ppm.

### Claim 69 (depends on 63, 64, 65, 66, 67, 68)

The method of any one of claims 63 to 68, wherein the formulation has a pH of from about 5 to about 7.

### Claim 70 (depends on 69)

The method of claim 69, wherein the formulation has a pH of from about 5.4 to about 6.4.

### Claim 71 (depends on 69)

The method of claim 69, wherein the formulation has a pH of from about 5.0 to about 6.4.

### Claim 72 (depends on 63, 64, 65, 66, 67, 68, 69, 70, 71)

The method of any one of claims 63 to 71, wherein the condition is Actinic keratosis, UV damage, or sunburn.

### Claim 73 (depends on 63, 64, 65, 66, 67, 68, 69, 70, 71, 72)

The method of any one of claims 63 to 72, wherein the hypochlorous acid formulation is applied to affected areas from 1 to about 10 times daily.

### Claim 74 (depends on 73)

The method of claim 73, wherein the hypochlorous acid formulation is applied to affected areas from 1 to about 5 times daily.

### Claim 75 (depends on 73)

The method of claim 73, wherein the hypochlorous acid formulation is applied to affected areas from 1 to about 3 times daily.

### Claim 76 (depends on 73, 74, 75)

The method of any one of claims 73 to 75, wherein the hypochlorous acid formulation is applied in a regimen that lasts for 1 to about 12 weeks.

### Claim 77 (depends on 76)

The method of claim 76, wherein the hypochlorous acid formulation is applied in a regimen that lasts for 1 to about 8 weeks.

### Claim 78 (depends on 76)

The method of claim 76, wherein the hypochlorous acid formulation is applied in a regimen that lasts for 1 to about 4 weeks.

### Claim 79

A method for treating an immunological disorder involving the skin, comprising: applying to the affected areas of the skin a a hypochlorous acid formulation having an amount of hypochlorous acid effective to reduce or inhibit inflammatory and/or immune processes.

### Claim 80 (depends on 79)

The method of claim 79, wherein the formulation has AFC of at least about 300 ppm.

### Claim 81 (depends on 79)

The method of claim 79, wherein the formulation has AFC of at least about 500 ppm.

### Claim 82 (depends on 79)

The method of claim 79, wherein the formulation has AFC of at least about 700 ppm.

### Claim 83 (depends on 79)

The method of claim 79, wherein the formulation has AFC of at least about 1000 ppm.

### Claim 84 (depends on 79)

The method of claim 79, wherein the AFC is in the range of about 500 to about 1500 ppm.

### Claim 85 (depends on 79, 80, 81, 82, 83, 84)

The method of any one of claims 79 to 84, wherein the formulation has a pH of from about 5 to about 7.

### Claim 86 (depends on 85)

The method of claim 85, wherein the formulation has a pH of from about 5.4 to about 6.4.

### Claim 87 (depends on 85)

The method of claim 85, wherein the formulation has a pH of from about 5.0 to about 6.4.

### Claim 88 (depends on 79, 80, 81, 82, 83, 84, 85, 86, 87)

The method of any one of claims 79 to 87, wherein the condition is atopic dermatitis or contact dermatitis, psoriasis, dermatitis herpetiformis, sarcoidosis, SLE, Sjogren's Syndrome, or allergic reaction.

### Claim 89 (depends on 79, 80, 81, 82, 83, 84, 85, 86, 87)

The method of any one of claims 79 to 87, wherein the hypochlorous acid formulation is applied to affected areas from 1 to about 10 times daily.

### Claim 90 (depends on 89)

The method of claim 89, wherein the hypochlorous acid formulation is applied to affected areas from 1 to about 5 times daily.

### Claim 91 (depends on 90)

The method of claim 90, wherein the hypochlorous acid formulation is applied to affected areas from 1 to about 3 times daily.

### Claim 92 (depends on 89, 90, 91)

The method of any one of claims 89 to 91, wherein the hypochlorous acid formulation is applied periodically to control symptoms or flare-ups.

### Claim 93 (depends on 92)

The method of claim 92, wherein the hypochlorous acid formulation is applied in a regimen that lasts for 1 to about 12 weeks.

### Claim 94 (depends on 92)

The method of claim 92, wherein the hypochlorous acid formulation is applied in a regimen that lasts for 1 to about 8 weeks.

### Claim 95 (depends on 92)

The method of claim 92, wherein the hypochlorous acid formulation is applied in a regimen that lasts for 1 to about 4 weeks.

### Claim 96

A method for treating pruritis, comprising: applying to the affected areas of the skin a hypochlorous acid formulation having an amount of hypochlorous acid effective to reduce or inhibit inflammatory and/or immune processes.

### Claim 97 (depends on 96)

The method of claim 96, wherein the formulation has AFC of at least about 300 ppm.

### Claim 98 (depends on 96)

The method of claim 96, wherein the formulation has AFC of at least about 500 ppm.

### Claim 99 (depends on 96)

The method of claim 96, wherein the formulation has AFC of at least about 700 ppm.

### Claim 100 (depends on 96)

The method of claim 96, wherein the formulation has AFC of at least about 1000 ppm.

### Claim 101 (depends on 96)

The method of claim 96, wherein the formulation has AFC in the range of about 500 to about 1500 ppm.

### Claim 102 (depends on 96, 97, 98, 99, 100, 101)

The method of any one of claims 96 to 101, wherein the formulation has a pH of from about 5 to about 7.

### Claim 103 (depends on 102)

The method of claim 102, wherein the formulation has a pH of from about 5.4 to about 6.4.

### Claim 104 (depends on 102)

The method of claim 102, wherein the formulation has a pH of from about 5.0 to about 6.4.

### Claim 105 (depends on 96, 97, 98, 99, 100, 101, 102, 103, 104)

The method of any one of claims 96 to 104, wherein the pruritis is a psychogenic itch or a neurogenic itch.

### Claim 106 (depends on 96, 97, 98, 99, 100, 101, 102, 103, 104, 105)

The method of any one of claims 96 to 105, wherein the hypochlorous acid formulation is applied to affected areas from 1 to about 10 times daily.

### Claim 107 (depends on 106)

The method of claim 106, wherein the hypochlorous acid formulation is applied to affected areas from 1 to about 5 times daily.

### Claim 108 (depends on 106)

The method of claim 106, wherein the hypochlorous acid formulation is applied to affected areas from 1 to about 3 times daily.

### Claim 109 (depends on 106, 107, 108)

The method of any one of claims 106 to 108, wherein the hypochlorous acid formulation is applied periodically to control symptoms or flare-ups.

### Claim 110 (depends on 109)

The method of claim 109, wherein the hypochlorous acid formulation is applied in a regimen that lasts for 1 to about 12 weeks.

### Claim 111 (depends on 109)

The method of claim 109, wherein the hypochlorous acid formulation is applied in a regimen that lasts for 1 to about 8 weeks.

### Claim 112 (depends on 109)

The method of claim 109, wherein the hypochlorous acid formulation is applied in a regimen that lasts for 1 to about 4 weeks.

### Claim 113

A hypochlorous acid hydrogel formulation: comprising available free chlorine (AFC) of at least 500 ppm, and which is at least 80% hypochlorous acid relative to the total of hypochlorous acid, hypochlorite, and Cl2; a pharmaceutically-acceptable silicate carrier for topical application; and sodium bicarbonate at from 500 to about 2000 mg/L.

### Claim 114 (depends on 113)

The formulation of claim 113, wherein the AFC is at least about 700 ppm.

### Claim 115 (depends on 113)

The formulation of claim 113, wherein the AFC is at least about 1000 ppm.

### Claim 116 (depends on 113)

The formulation of claim 113, wherein the AFC is in the range of about 500 to about 1500 ppm.

### Claim 117 (depends on 113, 114, 115, 116)

The formulation of any one of claims 113 to 116, wherein the formulation has a pH of from about 5 to about 7.

### Claim 118 (depends on 117)

The formulation of claim 117, wherein the formulation has a pH of from about 5.4 to about 6.4.

### Claim 119 (depends on 117)

The formulation of claim 117, wherein the formulation has a pH of from about 5.0 to about 6.4.

### Claim 120 (depends on 113, 114, 115, 116, 117, 118, 119)

The formulation of any one of claims 113 to 119, wherein the silicate carrier is sodium magnesium fluorosilicate or sodium lithium magnesium fluorosilicate.

### Claim 121 (depends on 113, 114, 115, 116, 117, 118, 119)

The formulation of any one of claims 113 to 119, wherein the formulation has a conductivity of from about 0.5 mS/cm to about 12 mS/cm.

### Claim 122 (depends on 121)

The formulation of claim 121, wherein the formulation has a conductivity of from about 1 mS/cm to about 10 mS/cm.

### Claim 123 (depends on 120)

The formulation of claim 120, wherein the formulation comprises from 0.5% to about 5% sodium magnesium fluorosilicate.

### Claim 124 (depends on 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123)

The formulation of any one of claims 113 to 123, further comprising phosphoric acid.

### Claim 125 (depends on 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124)

The formulation of any one of claims 113 to 124, having a viscosity of from about 500 to about 50000 cP.
